PRECISION ONCOLOGY
Advancing Cancer Diagnostics Through Organoid Innovation
Patient-derived organoid technology bridging the gap between laboratory discovery and clinical decision-making.
About RefinedOrganoids
RefinedOrganoids is a research-stage biotechnology company developing patient-derived organoid models for precision oncology. Based in Aurora, Colorado within the CU Anschutz Medical Campus corridor, we are building next-generation tools to guide cancer treatment decisions.
Our Platform
RefinedOrganoids delivers precision oncology solutions across four key areas:
Clinical Decision Support — Patient-derived organoid models to guide treatment selection and avoid ineffective therapies.
Drug Discovery & Rescue — Accelerate compound screening and identify new indications for existing drugs.
I/O Testing — Evaluate immunotherapy response in patient-specific tumor microenvironments.
Data Products — De-identified organoid response datasets for pharmaceutical research and biomarker discovery.
Leadership
Jeff Weness
CEO & Co-Founder
Jeff brings 17+ years of experience across healthcare, pharma/biotech, digital health, and corporate development. Prior to founding RefinedOrganoids, he led M&A, venture investments, and strategic partnerships at Otsuka Precision Health. Jeff holds an MBA from the University of Minnesota Carlson School of Management.